Scrip
20 April 2009
Nancy Faigen
Procter & Gamble is testing a programme through which it will back up the efficacy of Actonel (risedronate sodium) and reimburse a US insurer for the cost of treating non-spinal, osteoporosis-related fractures in patients on the product.
This would entail reimbursements for fractures...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
- Executive Briefing – Health technology assessment: a brief look at the EU
- Executive Briefing - Battle lines drawn over parallel trade
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
